These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32753854)

  • 1. Patient Reported Ease-of-Use with a Disposable Autoinjector in Individuals with Migraine.
    Mead J; Dammerman R; Rasmussen S
    Patient Prefer Adherence; 2020; 14():1137-1144. PubMed ID: 32753854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M; Leroux E; Pagé G
    Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies.
    Stauffer VL; Sides R; Lanteri-Minet M; Kielbasa W; Jin Y; Selzler KJ; Tepper SJ
    Patient Prefer Adherence; 2018; 12():1785-1795. PubMed ID: 30271122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
    Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
    Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
    Cherniakov I; Cohen-Barak O; Tiver R; Gillespie M; Kessler Y; Gutierrez M; Rasamoelisolo M; Li S; Shen H; Hallak H; Loupe PS; Smith M; Rabinovich-Guilatt L; Spiegelstein O
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1018-1027. PubMed ID: 33411992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.
    Callis Duffin K; Bukhalo M; Bobonich MA; Shrom D; Zhao F; Kershner JR; Gill A; Pangallo B; Shuler CL; Bagel J
    Med Devices (Auckl); 2016; 9():361-369. PubMed ID: 27785115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients.
    Brand-Schieber E; Munjal S; Kumar R; Andre AD; Valladao W; Ramirez M
    Med Devices (Auckl); 2016; 9():131-7. PubMed ID: 27313479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes.
    Schoenen J; Timmermans G; Nonis R; Manise M; Fumal A; Gérard P
    Front Neurol; 2021; 12():805334. PubMed ID: 34956071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.
    Giamberardino MA; Affaitati G; Costantini R; Cipollone F; Martelletti P
    J Pain Res; 2017; 10():2751-2760. PubMed ID: 29263689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers.
    Faust E; Pivneva I; Yang K; Betts KA; Ahmed Z; Joshi S; Hogan R; Blumenfeld A; Schim J; Feoktistov A; Carnes K; Bensink M; Wu EQ; Chou DE; Chandler D
    Neurol Ther; 2021 Jun; 10(1):293-306. PubMed ID: 33856626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs.
    Andre AD; Brand-Schieber E; Ramirez M; Munjal S; Kumar R
    Patient Prefer Adherence; 2017; 11():121-129. PubMed ID: 28176899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erenumab in the treatment of migraine.
    Andreou AP; Fuccaro M; Lambru G
    Ther Adv Neurol Disord; 2020; 13():1756286420927119. PubMed ID: 32523630
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.